Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151470 | 0.88 | TAAR1 (0.52) | TAAR1FFAR1FFAR4AOC3MEN1 | |
| SCHEMBL8764227 | 0.84 | MEN1 (0.52) | FFAR1FFAR4MEN1KMT2AKDM4E | |
| SCHEMBL3556279 | 0.83 | MEN1 (0.45) | TAAR1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL5536006 | 0.78 | TAAR1 (0.56) | TAAR1AOC3IDO1MPODAO | |
| SCHEMBL5538107 | 0.78 | TAAR1 (0.56) | TAAR1AOC3IDO1MPODAO | |
| SCHEMBL8526001 | 0.78 | TAAR1 (0.75) | TAAR1AOC3IDO1MPODAO | |
| SCHEMBL8763171 | 0.77 | MEN1 (0.46) | FFAR1FFAR4MEN1KMT2AKDM4E | |
| SCHEMBL29734785 | 0.77 | TAAR1 (0.48) | TAAR1FFAR1FFAR4AOC3MEN1 | |
| SCHEMBL103401 | 0.77 | TAAR1 (0.48) | TAAR1FFAR1FFAR4AOC3MEN1 | |
| SCHEMBL24595070 | 0.76 | MEN1 (0.39) | TAAR1FFAR1FFAR4AOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | MEDPACTO INC. (KR) | 2023-09-28 | — | — | US | disclosed |
| CN-112645841-A | 2-fluorobenzonitrile derivative and preparation method and application thereof | 上海工程技术大学 | 2021-04-13 | — | — | CN | disclosed |
| WO-2015118434-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS KINASE JAK-2 INHIBITORS | CELON PHARMA S.A. (PL) | 2015-08-13 | — | — | WO | disclosed |
| CN-102134214-B | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2013-05-22 | — | — | CN | disclosed |
| WO-2012175514-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| CN-102134214-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA SWEDEN AB | 2011-07-27 | — | — | CN | disclosed |
| WO-2011076687-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076687-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | WO | disclosed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| CN-1107068-C | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo (3,2-D] pyrimidine-4-ones | NOVARTIS AG (CH) | 2003-04-30 | — | — | CN | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
| CN-1257503-A | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo (3,2-D] pyrimidine-4-ones | NOVARTIS AG (CH) | 2000-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | TGFB1, TGFBR1, TGFB2 | TAAR1 3229/4885FFAR1 4185/4885FFAR4 4698/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | TAAR1 1034/4885FFAR1 298/4885FFAR4 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.